Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories audit-Related Fees ($M) ($M)
Form DEF 14A Proxy Statement (Audit Fees)
Latest, FY2025
1,664,000
Period ended Dec 31, 2025
Change on a year earlier
+5.7%
1,574,000 in FY2024
History
8 years
Since FY2018
Sources
7
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Audit-Related Fees ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,664,000 | +5.7% | SEC Filing (0001308179-26-000064) ↗ |
| FY2024 | Dec 31, 2024 | 1,574,000 | +12.2% | SEC Filing (0001308179-26-000064) ↗ |
| FY2023 | Dec 31, 2023 | 1,403,000 | -11.6% | SEC Filing (0001308179-25-000134) ↗ |
| FY2022 | Dec 31, 2022 | 1,587,000 | -1.7% | SEC Filing (0001308179-24-000182) ↗ |
| FY2021 | Dec 31, 2021 | 1,615,000 | +39.5% | SEC Filing (0001308179-23-000247) ↗ |
| FY2020 | Dec 31, 2020 | 1,158,000 | +12.5% | SEC Filing (0001206774-22-000778) ↗ |
| FY2019 | Dec 31, 2019 | 1,029,000 | +33.6% | SEC Filing (0001047469-21-000592) ↗ |
| FY2018 | Dec 31, 2018 | 770,000 | – | SEC Filing (0001047469-20-001466) ↗ |
Cite this data
StockData. (2026). Abbott Laboratories Audit-Related Fees ($M) ($M), annual FY2018–FY2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/audit-rel-fees
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.